Literature DB >> 25472580

SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.

Yong Liu1, Xuegang Luo, Jingyu Deng, Yuan Pan, Li Zhang, Han Liang.   

Abstract

SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase, plays a key function in the progression of human cancer. However, the role of SMYD3 in gastric carcinoma carcinogenesis has yet to be elucidated. This study aimed to determine the relationships of SMYD3 expression with clinicopathological characteristics and prognosis in gastric carcinoma. The expression of SMYD3 was detected by real-time quantitative reverse transcription PCR and Western blot in gastric carcinoma (GC) cell lines, normal gastric mucosa cell line, GC tissues, and adjacent non-tumor tissues. SMYD3 expression in tissue sections of 180 gastric carcinoma samples were evaluated using immunohistochemistry. The staining results were compared with clinicopathological characteristics and to the outcome of patients. The expression levels of SMYD3 messenger RNA (mRNA) and protein in GC tissues were both higher than those in adjacent non-tumor tissues (p < 0.05). SMYD3 mRNA and protein expression levels were higher in GC cell lines MKN28, SGC7901, and MGC803 than normal gastric mucosa cell line GES-1. SMYD3 expression in gastric carcinoma was significantly correlated with primary tumor size (p < 0.001), lymph node metastasis (p < 0.001), and TNM stage (p = 0.011). Degree of differentiation [hazard ratio (HR) = 5.113; p = 0.006], serosal invasion (HR = 2.074; p = 0.024), lymph node metastasis (HR = 1.354; p < 0.001), and SMYD3 expression (HR = 0.564; p = 0.004) were identified as the independent factors of the overall survival (OS) in all enrolled GC patients. For patients with positive lymph node metastasis, degree of differentiation (HR = 5.974; p = 0.015), lymph node metastasis (HR = 1.257; p < 0.001), and SMYD3 expression (HR = 0.529; p = 0.004) were the independent prognostic factors of the OS. SMYD3 performed an important function in the aggressiveness of gastric carcinoma and may act as a promising target for prognostic prediction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25472580     DOI: 10.1007/s13277-014-2891-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  The prognostic analysis of lymph node-positive gastric cancer patients following curative resection.

Authors:  Jingyu Deng; Han Liang; Dan Sun; Yi Pan
Journal:  J Surg Res       Date:  2009-01-10       Impact factor: 2.192

2.  Risk factors predictive of lymph node metastasis in depressed early gastric cancer.

Authors:  Nobutsugu Abe; Takashi Watanabe; Kazufumi Suzuki; Hiromichi Machida; Hiroshi Toda; Yuzo Nakaya; Tadahiko Masaki; Toshiyuki Mori; Masanori Sugiyama; Yutaka Atomi
Journal:  Am J Surg       Date:  2002-02       Impact factor: 2.565

3.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

Authors:  S B Jakowlew; R Breathnach; J M Jeltsch; P Masiakowski; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

4.  Correlation of RKIP, STAT3 and cyclin D1 expression in pathogenesis of gastric cancer.

Authors:  Xiao-Mei Zhang; Chuanwen Zhou; Huan Gu; Lu Yan; Gui-Ying Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Analysis of 154 actual five-year survivors of gastric cancer.

Authors:  S N Hochwald; S Kim; D S Klimstra; M F Brennan; M S Karpeh
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

Review 6.  Incidence and mortality of gastric cancer in China.

Authors:  Ling Yang
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

7.  Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.

Authors:  Tian-nian Ren; Jing-song Wang; Yun-mian He; Chang-liang Xu; Shu-zhen Wang; Tao Xi
Journal:  Med Oncol       Date:  2010-10-19       Impact factor: 3.064

8.  The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.

Authors:  Masaki Kunizaki; Ryuji Hamamoto; Fabio Pittella Silva; Kiyoshi Yamaguchi; Takeshi Nagayasu; Masabumi Shibuya; Yusuke Nakamura; Yoichi Furukawa
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.

Authors:  Ryuji Hamamoto; Yoichi Furukawa; Masashi Morita; Yuko Iimura; Fabio Pittella Silva; Meihua Li; Ryuichiro Yagyu; Yusuke Nakamura
Journal:  Nat Cell Biol       Date:  2004-07-04       Impact factor: 28.824

10.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

Authors:  Li-Bo Chen; Jun-Yao Xu; Zhen Yang; Guo-Bin Wang
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

View more
  18 in total

1.  SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.

Authors:  Qing-Qing Dong; Qiu-Tong Wang; Lei Wang; Ya-Xin Jiang; Mei-Ling Liu; Hai-Jie Hu; Yong Liu; Hao Zhou; Hong-Peng He; Tong-Cun Zhang; Xue-Gang Luo
Journal:  Food Sci Biotechnol       Date:  2018-03-22       Impact factor: 2.391

2.  Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.

Authors:  Yong Liu; Honggen Liu; Xuegang Luo; Jingyu Deng; Yuan Pan; Han Liang
Journal:  Tumour Biol       Date:  2015-01-28

3.  Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.

Authors:  Dongju Chen; Lei Liu; Xuegang Luo; Ai Mu; Lihua Yan; Xiaoying Chen; Lei Wang; Nan Wang; Hongpeng He; Hao Zhou; Tongcun Zhang
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

4.  Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Authors:  Lorna H Mitchell; P Ann Boriack-Sjodin; Sherri Smith; Michael Thomenius; Nathalie Rioux; Michael Munchhof; James E Mills; Christine Klaus; Jennifer Totman; Thomas V Riera; Alejandra Raimondi; Suzanne L Jacques; Kip West; Megan Foley; Nigel J Waters; Kevin W Kuntz; Tim J Wigle; Margaret Porter Scott; Robert A Copeland; Jesse J Smith; Richard Chesworth
Journal:  ACS Med Chem Lett       Date:  2015-08-27       Impact factor: 4.345

Review 5.  SET and MYND domain containing protein 3 in cancer.

Authors:  Lei Huang; A-Man Xu
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

6.  Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.

Authors:  Bing Shen; Mingyue Tan; Xinyu Mu; Yan Qin; Fang Zhang; Yong Liu; Yu Fan
Journal:  Tumour Biol       Date:  2015-12-16

7.  Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.

Authors:  Pushkar Chandra; Ruhi Dixit; Arvind Pratap; Suman Mishra; Rajnikant Mishra; Vijay Kumar Shukla
Journal:  Indian J Surg Oncol       Date:  2020-07-11

8.  ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.

Authors:  Lei Wang; Qiu-Tong Wang; Yu-Peng Liu; Qing-Qing Dong; Hai-Jie Hu; Zhi Miao; Shuang Li; Yong Liu; Hao Zhou; Tong-Cun Zhang; Wen-Jian Ma; Xue-Gang Luo
Journal:  J Gastric Cancer       Date:  2017-11-15       Impact factor: 3.720

9.  Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.

Authors:  Yuichiro Yoshioka; Takehiro Suzuki; Yo Matsuo; Giichiro Tsurita; Toshiaki Watanabe; Naoshi Dohmae; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Cancer Med       Date:  2017-06-22       Impact factor: 4.452

10.  A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.

Authors:  Alessia Peserico; Aldo Germani; Paola Sanese; Armenio Jorge Barbosa; Valeria Di Virgilio; Raffaella Fittipaldi; Edoardo Fabini; Carlo Bertucci; Greta Varchi; Mary Pat Moyer; Giuseppina Caretti; Alberto Del Rio; Cristiano Simone
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.